ClinicalTrials.gov
Cure8 trial brief
Why This Matters
Pouchitis is a common problem after colectomy with J‑pouch in ulcerative colitis and there are limited options to prevent it. If Aquamin® lowers inflammation or improves gut barrier measures, it could become a low‑risk preventive strategy pending trial results.
Who Should Pay Attention
Adults with ulcerative colitis who have had recent J‑pouch (IPAA) surgery, gastroenterologists and colorectal surgeons caring for pouch patients, and researchers studying pouchitis prevention or mineral/nutrient interventions.
Study Snapshot
Story typeClinical Reference
Trial phasePhase 2
Enrollment52 participants
Study statusRecruiting
Source depthTrial registry record
What To Know
This randomized study plans to enroll about 52 adults with a newly formed J‑pouch and will compare Aquamin® (2400 mg/day, ≈800 mg calcium) versus placebo for 365 days.
The study will monitor time to clinical pouchitis using the Modified Pouchitis Disease Activity Index and measure gut permeability with lactulose:mannitol testing at baseline, 180 days, and 365 days.
The trial excludes people with Crohn’s disease, active kidney disease or recent kidney stones, recent use of calcium/magnesium supplements, NSAIDs, systemic corticosteroids, or antibiotics (with specific washout rules). It is recruiting at the University of Michigan.
What this does not tell you: This is a protocol record of an ongoing Phase 2 trial; it does not report results or prove benefit or safety of Aquamin® for preventing pouchitis.
Keep In Mind
This entry is a clinicaltrials.gov trial record (Phase 2, recruiting). It describes the planned design, interventions, eligibility, and outcome measures but does not present results. Aquamin® is a commercial multi‑mineral supplement; trial outcomes are needed before changing care.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorMuhammad N Aslam, MD
Trial IDNCT07501078
Study typeInterventional
Trial phasePhase 2
Enrollment52 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedAug 26, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Aquamin® as an Adjuvant Intervention for Ulcerative Colitis
A dietary multi-mineral supplement is being tested in a Phase 2 trial to see if it can improve symptoms, influence inflammation biomarkers, and help induce or maintain remission in people with ulcerative colitis.
A Phase 2 Study of D-2570 in Subjects With Moderately to Severely Active Ulcerative Colitis
This trial tests an investigational oral therapy (D-2570) specifically in moderate–severe ulcerative colitis with a standard clinical remission endpoint at 12 weeks. Results could inform new treatment options if later...
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
This trial tests whether adding an investigational oral agent (LY4268989) to mirikizumab improves remission rates in people with moderately to severely active ulcerative colitis. If successful, it could expand treatment...